Peptides explained
TB-500: how it works
Also known as: Thymosin-beta-4-related material
Page updated · Sources and editorial approach
TB-500 and thymosin beta-4 explained: identity, actin and cell-migration biology, wound models and why sequence differences change the evidence.
TB-500 at a glance
What it does biologically
The name is associated with thymosin-beta-4-related materials. Full-length thymosin beta-4 participates in actin-associated cell movement.
What the evidence shows
Published thymosin beta-4 experiments include wound and cell-migration models. They do not establish the effects of every material labelled TB-500.
What remains uncertain
The exact sequence and formulation must be known before assigning evidence to a TB-500-labelled sample.
The basics
What is TB-500?
TB-500 is a commercial research label associated with thymosin beta-4 and related peptide material. The full-length protein and shorter fragments are not identical. A label alone is insufficient to determine which material is present.
This distinction matters when reading a study: the sequence, preparation and route should match the scientific question. Thymosin beta-4 results cannot simply be assigned to a differently defined fragment or a blend.
Biological action
How does TB-500 work?
Actin helps cells maintain shape and move. Thymosin beta-4 biology includes actin binding and processes involved in migration, blood-vessel formation and tissue responses to injury.
A 1999 study examined rat skin wounds and keratinocyte migration. It reported wound-related changes with full-length thymosin beta-4. It did not test a current commercial TB-500 pen or a BPC-157 combination.
Questions being investigated
What do studies examine?
Cell movement
Cell assays investigate migration, which is one part of a repair response.
Wound models
Rat experiments measured re-epithelialisation, collagen deposition and angiogenesis.
Sequence identity
Analytical confirmation is needed to connect a sample with the molecule studied.
Strength of evidence
How strong is the evidence?
Evidence is separated by level because a cell experiment, an animal model, a human trial and a regulatory decision answer different questions.
| Evidence type | What it tells us |
|---|---|
| Laboratory | Cell and tissue experiments exist for thymosin beta-4. |
| Animal | The linked primary wound study used rats and full-length thymosin beta-4. |
| Human | That preclinical experiment does not establish a human treatment effect for TB-500. |
| Regulatory | A TB-500 label does not establish an authorised medicine or clinical indication. |
Important context
Risks, limitations and unanswered questions
- Full-length protein, fragment and mixture evidence must remain separate.
- A rat skin wound is not a human tendon or joint condition.
- A positive mechanism does not establish acceptable long-term risk.
- A blend needs its own evidence and component-specific analytical testing.
Reading the original evidence
Identify what was actually studied
The linked wound experiment investigated thymosin beta-4 in rats and cell assays. A TB-500 name on a separate label does not demonstrate that it is the same material. Sequence and formulation need to match before even considering whether a study is relevant.
Question to take to the source: Does the paper name full-length thymosin beta-4, a fragment or another analogue, and is that distinction preserved in the summary?
Check the original source ↗For personal accounts and research questionnaires, read user feedback and patient-reported outcomes.
Detailed catalogue research
TB-500 vs thymosin beta-4: sequence and wound research
See why full-length thymosin beta-4 and the fragment associated with TB-500 must be identified separately when reading research.
Is TB-500 the same molecule as full-length thymosin beta-4?
Some references use TB-500 for a short fragment of thymosin beta-4. Full-length thymosin beta-4 is a longer molecule. A shared part of the amino-acid sequence is not enough to infer identical activity, stability or tissue exposure. Start with the exact sequence in the methods or regulatory document. A study that identifies full-length thymosin beta-4 should be cited using that name.
What did thymosin beta-4 wound studies measure?
A 1999 study applied full-length thymosin beta-4 in a rat model of full-thickness skin wounds and also examined cell migration. Skin closure and migration are relevant to the biology of skin repair. The experiment did not test a commercial TB-500 blend, a torn human tendon or a return-to-sport outcome. Its findings are a starting point for research on a defined molecule and model.
What can an analytical result establish about TB-500?
A meaningful identity result needs a defined expected sequence or other identifying reference. A purity percentage indicates something about the components detected by a specified method. It does not substitute for establishing which fragment is present. Where a paper tested a different sequence, use the paper as biological context and keep the clinical claims for the material in question separate.
Sources for this research section
Questions answered
TB-500 FAQs
Is TB-500 always full-length thymosin beta-4?
Do not assume so. Confirm the sequence and analytical identity rather than relying on the commercial name.
Does a wound study prove human injury recovery?
No. Species, tissue, sequence and formulation differences all matter.
Is combining TB-500 and BPC-157 proven to work better?
Separate component findings do not establish added benefit from the mixture.
Check the sources
Sources and further reading
Follow the original study or official information to check the population, methods and full results. Reviews and sponsor updates are labelled below.
- Malinda et al.: thymosin beta-4 and wound repair ↗Primary rat wound and cell-migration study using thymosin beta-4.
- FDA document identifying the fragment nominated as TB-500 ↗Source for the detailed research section.
Educational information, prepared with AI assistance and not independently clinically reviewed. It is not personal medical advice or a treatment recommendation. Read the editorial policy or suggest a correction.